Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China

被引:7
|
作者
Li, Heng
Xiong, Wenjie
Liu, Huimin
Yi, Shuhua
Yu, Zhen
Liu, Wei
Lyu, Rui
Wang, Tingyu
Zou, Dehui
Li, Zengjun
Qiu, Lugui
机构
[1] Chinese Acad Med Sci, State Key Lab Expt Hematol, Inst Hematol, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China
[3] Peking Union Med Coll, Tianjin 300020, Peoples R China
[4] Chinese Acad Med Sci, Dept Lymphoma & Myeloma, Inst Hematol, Tianjin 300020, Peoples R China
关键词
17p deletion; chronic lymphocytic leukemia (CLL); fluorescent in situ hybridization (FISH); del17p in CLL; HIGH-DOSE METHYLPREDNISOLONE; LRF CLL4 TRIAL; RITUXIMAB; THERAPY; CYCLOPHOSPHAMIDE; FLUDARABINE; SURVIVAL; ABNORMALITIES; ALEMTUZUMAB; ABERRATIONS;
D O I
10.21147/j.issn.1000-9604.2017.02.09
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This study aims to evaluate the natural history of patients with chronic lymphocytic leukemia (CLL) and a 17p deletion (17p-) and identify the predictive factors within this subgroup. Methods: The sample of patients with CLL were analyzed by fluorescence in situ hybridization for deletions in chromosome bands 11q22, 13q14 and 17p13; trisomy of bands 12q13; and translocation involving band 14q32. The data from 456 patients with or without a 17p-were retrospectively collected and analyzed. Results: The overall response rate (ORR) in patients with a 17p- was 56.9%, and patients with a high percentage of 17p-(defined as more than 25% of cells harbouring a 17p-) had a lower ORR. The median overall survival (OS) in patients with a 17p-was 78.0 months, which was significantly shorter than the OS in patients without this genetic abnormality (median 162.0 months, P<0.001). Within the subgroup with a 17p-, the progression-free survival was significantly shorter in patients at Binet stage B-C and patients with elevated lactate dehydrogenase (LDH), B symptoms, unmutated IGHV and a high percentage of 17p-. Conclusions: These results indicated that patients with a 17p- CLL have a variable prognosis that might be predicted using simple clinical and laboratory characteristics.
引用
收藏
页码:156 / 165
页数:10
相关论文
共 50 条
  • [41] Overexpression of Galectin-3 in Chronic Lymphocytic Leukemia Is Associated With 17p Deletion: A Short Report
    Michalova, Zuzana
    Coma, Matus
    Kicova, Miroslava
    Gabzdilova, Juliana
    Dedinska, Kinga
    Guman, Tomas
    Hajikova, Martina
    Veselinyova, Dominika
    Giertlova, Maria
    Gal, Peter
    Sarissky, Marek
    ANTICANCER RESEARCH, 2019, 39 (06) : 2805 - 2810
  • [42] Chronic Lymphocytic Leukemia With Deletion 17p: Emerging Treatment Options THE STEPHENS/BYRD ARTICLE REVIEWED
    Jain, Nitin
    O'Brien, Susan
    ONCOLOGY-NEW YORK, 2012, 26 (11): : 1067 - +
  • [43] Allogeneic Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia With 17p Deletion: A Retrospective European Group for Blood and Marrow Transplantation Analysis
    Schetelig, Johannes
    van Biezen, Anja
    Brand, Ronald
    Caballero, Dolores
    Martino, Rodrigo
    Itala, Maija
    Garcia-Marco, Jose A.
    Volin, Liisa
    Schmitz, Norbert
    Schwerdtfeger, Rainer
    Ganser, Arnold
    Onida, Francesco
    Mohr, Brigitte
    Stilgenbauer, Stephan
    Bornhaeuser, Martin
    de Witte, Theo
    Dreger, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (31) : 5094 - 5100
  • [44] Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE™-17 Trial
    O'Brien, Susan
    Jones, Jeffrey A.
    Coutre, Steven
    Mato, Anthony R.
    Hillmen, Peter
    Tam, Constantine
    Osterborg, Anders
    Siddiqi, Tanya
    Thirman, Michael J.
    Furman, Richard R.
    Ilhan, Osman
    Keating, Michael
    Call, Timothy G.
    Brown, Jennifer R.
    Stevens-Brogan, Michelle
    Li, Yunfeng
    Fardis, Maria
    Clow, Fong
    James, Danelle F.
    Chu, Alvina D.
    Hallek, Michael
    Stilgenbauer, Stephan
    BLOOD, 2014, 124 (21)
  • [45] Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Schetelig, Johannes
    Hillmen, Peter
    Seymour, John F.
    Coutre, Steven
    Jurczak, Wojciech
    Mulligan, Stephen P.
    Schuh, Anna
    Assouline, Sarit
    Wendtner, Clemens-Martin
    Roberts, Andrew W.
    Davids, Matthew S.
    Bloehdorn, Johannes
    Munir, Talha
    Boettcher, Sebastian
    Zhou, Lang
    Salem, Ahmed Hamed
    Desai, Monali
    Chyla, Brenda
    Arzt, Jennifer
    Kim, Su Young
    Verdugo, Maria
    Gordon, Gary
    Hallek, Michael
    Wierda, William G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (19) : 1973 - +
  • [46] Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion
    Forconi, Francesco
    Rinaldi, Andrea
    Kwee, Ivo
    Sozzi, Elisa
    Raspadori, Donatella
    Rancoita, Paola M. V.
    Scandurra, Marta
    Rossi, Davide
    Deambrogi, Clara
    Capello, Daniela
    Zucca, Emanuele
    Marconi, Daniela
    Bomben, Riccardo
    Gattei, Valter
    Lauria, Francesco
    Gaidano, Gianluca
    Bertoni, Francesco
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (04) : 532 - 536
  • [47] Combined chronic myeloid leukaemia and chronic lymphocytic leukaemia in five patients, including one with 17p deletion
    Armarego, Michael
    Gottlieb, David
    Dunlop, Lindsay
    Cooney, Julian P.
    INTERNAL MEDICINE JOURNAL, 2021, 51 (04) : 580 - 584
  • [48] Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult-no-transplant analysis
    Poon, Michelle L.
    Fox, Patricia S.
    Samuels, Barry I.
    O'Brien, Susan
    Jabbour, Elias
    Hsu, Yvonne
    Gulbis, Alison
    Korbling, Martin
    Champlin, Richard
    Abruzzo, Lynne V.
    Bassett, Roland L., Jr.
    Khouri, Issa F.
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 711 - 715
  • [49] Treatment patterns and best response in a contemporary sample of refractory or relapsed chronic lymphocytic leukemia patients with 17p deletion in the United States
    Lamanna, Nicole
    Hurst, Deborah
    Latremouille-Viau, Dominick
    Ionescu-Ittu, Raluca
    Guerin, Annie
    Reyes, Carolina
    LEUKEMIA & LYMPHOMA, 2015, 56 : 148 - 149
  • [50] A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib
    Mato, Anthony R.
    Tang, Boxiong
    Azmi, Soraya
    Yang, Keri
    Zhang, Xiaojuan
    Stern, Jennifer C.
    Hedrick, Eric
    Huang, Jane
    Sharman, Jeff P.
    HAEMATOLOGICA, 2022, 107 : 2630 - 2640